Is your feature request related to a problem? Please describe. The total tokens and context of the LLM gets overwhelmed in a short conversation with my agent. It's because the agent always gets ent ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.